Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 25
Filter
1.
Horm Metab Res ; 48(1): 16-9, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26566100

ABSTRACT

The pregnancy outcomes in women with gestational diabetes mellitus (GDM) and 'overt diabetes in pregnancy' were compared and the need for further subclassification was investigated with respect to postpartum outcome risk. Data from 944 women who had been uniformly diagnosed as having GDM in Munich, Germany, between 1998 and 2010, were re-classified into GDM and 'overt diabetes in pregnancy'. Pregnancy related outcomes in the offspring were derived from Bavarian birth registry data. Classification and regression trees were used to identify further GDM sub-phenotypes. In total, 88 women (9.3%) were re-classified as having 'overt diabetes in pregnancy'. Compared to women with GDM, women with 'overt diabetes in pregnancy' used insulin more frequently, and were at increased risk for large for gestational age infants [odds ratio 2.50 (95% confidence interval 1.02, 6.13)], preterm delivery [odds ratio 3.28 (1.02, 10.50)], and low APGAR-score at 5 min [odds ratio 12.70 (1.58, 102.2)]. In the 856 women with GDM, classification and regression tree analyses provided further risk stratification in that a combination of fasting glucose>5.3 mmol/l and 1-h glucose>11.1 mmol/l at GDM diagnosis predicted insulin requirement [OR 5.57 (3.75, 8.27) compared to the rest], and maternal body mass index (BMI)≥35 kg/m(2) predicted large for gestational age status. The new differentiation between GDM and 'overt diabetes in pregnancy' is a first step towards refining classification relevant to fetal and maternal postpartum risk. A combination of glucose levels and maternal BMI at diagnosis of GDM may provide further improvement.


Subject(s)
Diabetes, Gestational/epidemiology , Risk Assessment , World Health Organization , Adult , Confidence Intervals , Female , Humans , Odds Ratio , Pregnancy , Pregnancy Outcome , Prevalence , Regression Analysis
5.
MMW Fortschr Med ; 149(37): 41-4, 2007 Sep 13.
Article in German | MEDLINE | ID: mdl-17918462

ABSTRACT

Chronic heart failure (CHF) in patients with diabetes mellitus (DM) is a condition that is frequent and has a poor prognosis. Diabetes mellitus is an independent risk factor for CHF and vice versa. CHF is found in 10-15% of the patients with DM compared to 3% in individuals without DM. Apart from CHD and hypertension, hyperglycaemia and insulin resistance are directly linked to the development of diastolic dysfunction and to CHF. According to the stepwise diagnostic procedure recommended by the ESC in its guidelines from 2005, if heart failure is suspected, the disease should first be diagnosed by ECG, X-ray, or testing for natriuretic peptide and followed by echocardiography when test results are abnormal. Treatment of CHF in patients with diabetes mellitus is the same as that for nondiabetic patients and includes the use of ACEIs, ARBSs (as an alternative to or in combination with ACEIs), BBs, diuretics (in particular loop diuretics), aldosterone inhibitors and digitalis. Most importantly, meticulous glucose control is a must in patients with diabetes mellitus and CHF to improve prognosis. Contraindications for antidiabetic drugs such as glitazones for CHF-NYHA classes I-IV and metformin for NYHA classes III-IV need to be considered in patients with CHF and diabetes mellitus.


Subject(s)
Diabetes Complications/etiology , Heart Failure/etiology , Cardiomyopathies/complications , Cardiomyopathies/drug therapy , Cardiovascular Agents/therapeutic use , Coronary Disease/complications , Coronary Disease/drug therapy , Diabetes Complications/drug therapy , Diabetic Angiopathies/complications , Diabetic Angiopathies/drug therapy , Heart Failure/drug therapy , Humans , Hypoglycemic Agents/therapeutic use , Prognosis , Risk Factors
6.
Exp Clin Endocrinol Diabetes ; 115(1): 62-4, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17286239

ABSTRACT

We report on the first two Caucasian families with the MODY3 HNF-1alpha mutation Tyr218Cys. Clinical and laboratory examinations are shown in detail. Patients with HNF-1alpha related MODY may develop the full spectrum of diabetic complications. Therefore, early detection of family members with MODY3 is warranted.


Subject(s)
Diabetes Complications/genetics , Diabetes Mellitus, Type 2/genetics , Hepatocyte Nuclear Factor 1-alpha/genetics , Mutation, Missense , Adolescent , Adult , Diabetes Complications/metabolism , Diabetes Mellitus, Type 2/metabolism , Family , Female , Hepatocyte Nuclear Factor 1-alpha/metabolism , Humans , Male , Middle Aged , Pedigree , White People
7.
MMW Fortschr Med ; 148(20): 47-50, 2006 May 18.
Article in German | MEDLINE | ID: mdl-16805191

ABSTRACT

Differentiation of the various forms of diabetes is necessary for therapeutic reasons. Typical signs of type 2 diabetes are age over 40, obesity, and other markers for metabolic syndrome, a positive famitory, gradual development of the classical symptoms, and no evidence of ketosis. It is important to distinguish this from LADA (latent autoimmune diabetes of adulthood), a form of type 1 diabetes mellitus. To establish this differential diagnosis antibody testing is employed. Antibody tests in patients with newly manifest diabetes make good sense when the clinical diagnosis is not unequivocal, that is, to distinguish it from type 2 diabetes, MODY diabetes, hereditary and secondary forms. At present, immunodiagnosis is used too often in unambiguous cases of type 1 diabetes, but too rarely in supposed type 2 diabetes. As a rule, LADA patients are GADA-positive. If MODY diabetes is suspected, a genetic examination is indicated. In patients with GDM, antibody testing with GADA makes sense, in particular in slim patients receiving insulin treatment, since these patients have a high risk for developing a postpartum diabetes already in the first years.


Subject(s)
Diabetes Mellitus, Type 1/diagnosis , Diabetes Mellitus, Type 2/diagnosis , Adolescent , Adult , Age Factors , Aged , Autoantibodies/blood , Autoimmune Diseases/classification , Autoimmune Diseases/diagnosis , Autoimmune Diseases/genetics , Child , Diabetes Mellitus, Type 1/classification , Diabetes Mellitus, Type 1/genetics , Diabetes Mellitus, Type 2/classification , Diabetes Mellitus, Type 2/genetics , Diabetes, Gestational/classification , Diabetes, Gestational/diagnosis , Diabetes, Gestational/genetics , Diagnosis, Differential , Female , Glutamate Decarboxylase/immunology , Humans , Male , Middle Aged , Pedigree , Pregnancy , Prognosis
8.
Internist (Berl) ; 47(4): 427, 429-33, 2006 Apr.
Article in German | MEDLINE | ID: mdl-16470359

ABSTRACT

A 62 year-old patient was admitted to hospital with rapid progressive edema, low potassium and hypertension. This symptoms are caused by Cushing's syndrome through ectopic paraneoplastic ACTH-production. Primary neoplasm is a small cell cancer. A Sertoli-cell-tumor of the testis was diagnosed as an additional carcinoma. Palliative chemotherapy and adrenostatic agents did not improve the clinical findings and the patient died eight weeks after admission.


Subject(s)
Cushing Syndrome/etiology , Edema/etiology , Hypertension/etiology , Hypokalemia/etiology , Sertoli Cell Tumor/complications , Testicular Neoplasms/complications , Testicular Neoplasms/diagnosis , Cushing Syndrome/diagnosis , Diagnosis, Differential , Disease Progression , Edema/diagnosis , Humans , Hypertension/diagnosis , Hypokalemia/diagnosis , Male , Middle Aged , Sertoli Cell Tumor/diagnosis
9.
Diabetologia ; 48(7): 1280-7, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15902401

ABSTRACT

AIMS/HYPOTHESIS: We have previously observed an inverse correlation between the incidence of type 1 diabetes and enterovirus infections in the background population. The aim of this study was to analyse whether maternal enterovirus antibody status, which reflects both the frequency of enterovirus infections and the protection conferred by the mother on the offspring, also correlates with the incidence of type 1 diabetes. METHODS: Maternal enterovirus antibodies were analysed from serum samples taken from pregnant women between 1983 and 2001 in Finland and Sweden using enzyme immunoassay and neutralisation assays. Comparable samples were also taken between 1999 and 2001 in countries with a lower incidence of diabetes (Estonia, Germany, Hungary, Israel, Lithuania, Russia). RESULTS: A clear decrease was observed in maternal enterovirus antibody levels over the past 20 years (p<0.0001). The frequency of enterovirus antibodies was higher in countries with a low or intermediate incidence of type 1 diabetes compared with high-incidence countries (p<0.0001). CONCLUSIONS/INTERPRETATION: These findings are in line with our previous observations supporting the hypothesis that a low frequency of enterovirus infection in the background population increases the susceptibility of young children to the diabetogenic effect of enteroviruses.


Subject(s)
Antibodies, Viral/blood , Diabetes Mellitus, Type 1/epidemiology , Enterovirus/immunology , Female , Finland/epidemiology , Geography , Humans , Immunoglobulin G/blood , Incidence , Neutralization Tests , Pregnancy , Sweden/epidemiology , Viral Plaque Assay
10.
Horm Metab Res ; 37(2): 63-7, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15778920

ABSTRACT

Splenocytes from prediabetic female NOD mice can transfer diabetes to NOD-SCID mice. Whereas the kinetics of disease transfer was shown to be a function of the age of donor splenocytes, information is scarce as to how the stage of autoimmune disease, as evaluated by pancreatic insulin content, is related to the diabetogenic potency of splenic T-cells. We therefore determined individual diabetes transfer times after an i. v. injection of splenocytes from prediabetic NOD mice of different ages into female NOD-SCID mice in relation to the diabetes incidence in NOD donor mice and their pancreatic insulin contents. Three groups (n = 8) of NOD mice aged 5, 11, and 17 weeks (wk) underwent splenectomy and hemipancreatectomy. After that, 10x10 (6) splenocytes either pooled from all donor NOD mice of the different age groups or individually from single donor mice were transferred to groups of four 6-week-old NOD-SCID mice, respectively, in two sets of experiments. Insulin was extracted from the resected hemipancreas, and the insulin content was determined by a RIA. Diabetes in the NOD-SCID cohort occurred after a mean time of 126 days after transfer of pooled splenocytes from 5-week-old NODs, after 68 days (transfer from 11-week-old NODs), and after a mean time of 43 days (transfer from 17-week-old NODs, 5 vs. 11 wk: p < 0.02, 11 vs. 17 wk: p < 0.001). Individual time to diabetes positively correlated with diabetes transfer times in NOD-SCID recipients (p < 0.0001) in the 17-week-old NOD mice, confirming previous diabetes transfer studies in hemi-pancreatectomized NOD mice. Furthermore, individual insulin concentrations in 17-week-old NOD mice also positively correlated to diabetes transfer times in recipient mice (p < 0.0001). No such correlations for these parameters were seen for the 5 and 11-week-old NOD mice (time to diabetes: 11 wk, p = 0.14, 5 wk, p = 0.75; insulin content: 11 wk, p = 0.81, 5 wk, p = 0.14). These data suggest that destructive T-cell activity increases during the course of islet autoimmunity. The immune response seems to be programmed for beta-cell destruction just before diabetes onset. This is the only time that pancreatic insulin content predicts the impending onset of diabetes.


Subject(s)
Diabetes Mellitus, Type 1/metabolism , Insulin/metabolism , Islets of Langerhans/metabolism , Prediabetic State/metabolism , T-Lymphocytes/transplantation , Animals , Diabetes Mellitus, Type 1/immunology , Female , Islets of Langerhans/immunology , Mice , Mice, Inbred NOD , Mice, SCID , Prediabetic State/immunology , Spleen/cytology , Spleen/immunology
11.
MMW Fortschr Med ; 146(35-36): 32-3, 35-6, 2004 Sep 02.
Article in German | MEDLINE | ID: mdl-15540536

ABSTRACT

The focus of current diabetes research is the clarification of the pathogenetic relationships between subclinical inflammation, diabetes and arteriosclerosis. Even minimal disturbances in glucose tolerance are associated with a chronic, generalized inflammatory reaction that links components of the metabolic syndrome and contributes to the development of diabetic complications as well as to the development and progression of arteriosclerosis. The most important mediators and markers of this inflammation cascade are NF-kappaB, TNF-alpha, IL-6, CRP and PAI-1. For the treatment of subclinical inflammation, substances with anti-inflammatory properties such as statins or ACE inhibitors are of increasing importance.


Subject(s)
Arteriosclerosis/etiology , Diabetes Mellitus, Type 2/etiology , Hypertension/etiology , Inflammation/complications , Obesity/complications , Adiponectin , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Aspirin/therapeutic use , Blood Glucose/analysis , Body Weight , C-Reactive Protein/analysis , Chronic Disease , Diabetes Mellitus, Type 1/blood , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/prevention & control , Exercise , Humans , Hypoglycemic Agents/therapeutic use , Hypolipidemic Agents/therapeutic use , Inflammation/drug therapy , Inflammation/etiology , Inflammation Mediators , Insulin/therapeutic use , Insulin Resistance , Intercellular Signaling Peptides and Proteins/blood , Intercellular Signaling Peptides and Proteins/physiology , Metabolic Syndrome , Research , Risk Factors , Rosiglitazone , Thiazolidinediones/therapeutic use
12.
Clin Exp Immunol ; 135(2): 318-21, 2004 Feb.
Article in English | MEDLINE | ID: mdl-14738462

ABSTRACT

Pregnancy is a natural state of immunoprotection and tolerance. We studied subjects with gestational diabetes (GDM) to evaluate the influence of pregnancy on the humoral immune response to the autoantigen GAD and to injected insulin. Antibodies against glutamic acid decarboxylase (GADA) subclasses and epitope reactivity were determined in 34 GADA-positive pregnant patients with GDM, in 20 GADA-positive relatives of people with TID and in 25 GADA-positive patients with newly diagnosed TID. Partum levels of insulin antibodies (IA), IgG1- and IgG4-IA were measured in 131 women with GDM treated with human insulin from the time of diabetes diagnosis (including 22 with GADA) and were compared to 19 patients with TID after 3 months of insulin treatment. GADA titre and subclasses were similar among all groups. GADA in GDM patients bound fewer epitopes than GADA in relatives of patients with TID (all epitopes being present in 23%versus 65%, P < 0.01). In particular, antibodies to the minor GADA epitopes GAD6596-249, GAD651-100 and GAD67 were less frequent in patients with GDM compared to relatives (P < 0.01). Antibodies to insulin (IA) were found in 17% of patients with GDM. They were more frequent in GDM patients with GADA compared to GADA-negative patients (41%versus 12%, P < 0.005). IgG1 was the dominant insulin antibody subclass response in both patients with GDM and TID but levels of IgG1-IA and IgG4-IA were significantly lower in patients with GDM compared to patients with TID (P < 0.004). Antibody responses in women with gestational diabetes appear to be dampened and restricted, but without change in subclass usage.


Subject(s)
Diabetes, Gestational/immunology , Glutamate Decarboxylase/immunology , Hypoglycemic Agents/immunology , Insulin/immunology , Adolescent , Adult , Autoantibodies/biosynthesis , Autoantibodies/immunology , Child , Diabetes Mellitus, Type 1/immunology , Diabetes, Gestational/drug therapy , Epitopes/immunology , Female , Humans , Hypoglycemic Agents/administration & dosage , Immunoglobulin G/analysis , Insulin/administration & dosage , Isoenzymes/immunology , Membrane Proteins/immunology , Middle Aged , Pregnancy , Prospective Studies
13.
Exp Clin Endocrinol Diabetes ; 111(5): 288-93, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12951636

ABSTRACT

Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is a rare autosomal recessive disorder, characterised by a loss of self-tolerance to endocrine tissues, chronic candidiasis and ectodermal disorders. APECED is associated with mutations of a single gene, designated autoimmune regulator (AIRE). We describe a 31-year-old APECED patient with non-traumatic, cutaneous ulcers on both forearms with features of a lupus-like panniculitis. On admission to the ICU in September 2001, the patient suffered from a ketoacidotic, hyperglycemic coma and adrenal crisis due to an Enterobacter-cloacae sepsis, originating from multiple, necrotising deep cutaneous ulcers. These ulcers spontaneously developed on both forearms, some of which were just emerging, full blown or healing with scars. Histological examination showed signs of a scarring panniculitis and vasculitis. Immunohistochemistry and direct immunofluorescence with characterisation of immunoglobulin and complement-factor binding pattern revealed features of a lupus-like panniculitis. Sequence analysis of all 14 exons of the AIRE gene revealed a R257 X mutation in exon 6 resulting in a nonsense mutation at codon 257 confirming the diagnosis of APECED. Oral treatment with 60 mg/day corticosteroids for two weeks led to complete resolution of all ulcers. In conclusion, mutations in the AIRE gene may provide the genetic background against which additional factors can initiate an autoimmune process. Here, autoimmune panniculitis appears to be an associated feature of the APECED syndrome. Our findings support the use of immunosuppressive therapy for autoimmune disease components of the APECED syndrome.


Subject(s)
Panniculitis, Lupus Erythematosus/diagnosis , Polyendocrinopathies, Autoimmune/diagnosis , Transcription Factors/genetics , Adult , Autoantibodies/blood , Biopsy , Candidiasis/complications , Candidiasis/diagnosis , Candidiasis/genetics , Codon, Nonsense , Female , Fluorescent Antibody Technique , Histocompatibility Testing , Humans , Immunosuppressive Agents/therapeutic use , Male , Panniculitis, Lupus Erythematosus/complications , Panniculitis, Lupus Erythematosus/drug therapy , Panniculitis, Lupus Erythematosus/genetics , Pedigree , Polyendocrinopathies, Autoimmune/complications , Polyendocrinopathies, Autoimmune/drug therapy , Polyendocrinopathies, Autoimmune/genetics , Skin/pathology , AIRE Protein
14.
Diabetologia ; 46 Suppl 1: M30-6, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12652356

ABSTRACT

Evidence obtained in the 1990's strongly supports the notion that glycaemic control is important not only in Type I (insulin-dependent), but also in Type II (non-insulin-dependent) diabetes mellitus. Although measurement of HbA(1c) is the standard for assessing the effect of glucose control in the occurrence and prevention of diabetic sequelae, more recent evidence indicates that other glucose parameters are also important. Postchallenge and postprandial hyperglycaemic peaks seem to be prospective determinants of vascular damage in early Type II diabetes. Currently, there is no overall accepted standard approach for the pharmacological management of Type II diabetes. The United Kingdom Prospective Diabetes Study has shown that reaching a near-normal glycaemic target is critically important and the pharmacotherapy of this progressive disease is difficult. Loss of endogenous insulin secretion has been substantiated to cause the progression of Type II diabetes in the United Kingdom Prospective Diabetes Study. Early insulinization, however, was not advantageous over other forms of therapy. The advent of polypharmacy in recent years has greatly strengthened the treatment of this disease. This synergy has been extended of late with the development of early-phase insulin secretion agents. Two such agents, nateglinide and repaglinide, can be used to reduce mealtime glucose excursions and HbA(1c) as monotherapy, and in combination with metformin; their antidiabetic potential is similar to the combination treatment with glibenclamide and metformin. Additional substantiation of their long-term effect on improving life expectancy and reducing diabetic complications in Type II diabetic patients is now required.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Hypoglycemic Agents/administration & dosage , Insulin/metabolism , Blood Glucose/analysis , Diabetes Mellitus, Type 2/physiopathology , Drug Therapy, Combination , Fasting , Food , Humans , Hyperglycemia , Insulin Resistance , Insulin Secretion , Phenotype
15.
Diabetologia ; 45(5): 677-85, 2002 May.
Article in English | MEDLINE | ID: mdl-12107748

ABSTRACT

AIMS/HYPOTHESIS: The aim of this study was to determine whether beta-cell autoimmunity is associated with immune response bias to exogenous antigens. METHODS: IgG subclass responses against tetanus toxoid and rubella were measured after vaccination in children with (n=36) and without (n=73) islet autoantibodies participating in the BABYDIAB prospective study of offspring of parents with Type I (insulin-dependent) diabetes mellitus. All children had been vaccinated against tetanus toxoid antigen before 6 months of age and at 18 months of age, and against live attenuated rubella virus at 18 months of age and again before 5 years of age. Tetanus toxoid specific IgG subclasses and cytokine responses were compared in a second cohort of subjects. RESULTS: Responses to tetanus toxoid in islet-autoantibody-negative children were characterized by early IgG1 antibodies at 9 months of age followed by the appearance of IgG4 and lesser IgG2 antibodies at 2 years of age. Children who had developed islet autoimmunity before one year of age (n=15) did not have the shift to IgG4 and IgG2 anti-TT after booster vaccination (p<0.01), and had undetectable or IgG1 restricted responses. This defect was independent of HLA class II genotype, was restricted to children who had islet autoimmunity before 1 year of age, and was most evident in children who already had multiple islet autoantibodies by 9 months of age. IgG4 and IgG2 anti-TT correlated with IL-4 (p<0.005), but not IFNgamma responses. Antibody responses to the IFNgamma-inducing rubella vaccination were strongly IgG1 dominated and no differences were observed between islet autoantibody positive and negative children. CONCLUSIONS/INTERPRETATION: These data are consistent with a reduced capacity to make IL-4 promoted antibody responses to exogenous antigen in early pre-diabetes.


Subject(s)
Antibody Formation , Diabetes Mellitus, Type 1/immunology , Immunoglobulin G/blood , Interleukin-4/immunology , Prediabetic State/immunology , Tetanus Toxoid/immunology , Aging , Female , Humans , Immunization Schedule , Infant , Male , Parents , Rubella Vaccine , Vaccines, Attenuated
16.
J Autoimmun ; 17(4): 333-40, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11771958

ABSTRACT

Recent case-control studies reported an increased frequency of antibodies against Coxsackie virus (CV) antigens in patients with newly diagnosed type 1 diabetes and during pregnancy in mothers of diabetic offspring, suggesting a role for CV infections in the pathogenesis of type 1 diabetes (T1D). However, it is not known whether CV infections are causally related to the development of islet autoantibodies or merely represent secondary events in subjects already affected with established islet autoimmunity. Therefore we have prospectively evaluated CV infections from birth, prior to and in parallel with the appearance of islet autoantibodies in offspring of parents with T1D. Using indirect ELISAs, IgG-antibodies (abs) against a panel of CV, and IgG- and IgM-abs to CVB3, CVB4, and CVB5 were measured at 9 months, 2, 5, and 8 years in 28 offspring of mothers or fathers with T1D or of mothers with gestational diabetes who developed persistent islet antibodies (IAA, GADA, IA-2A), and compared to 51 islet autoantibody-negative offspring matched for place and date of birth. CV infections were also determined at delivery in 16 mothers whose offspring developed islet autoantibodies later in life and compared to 110 mothers (matched for HLA-DR, place and date of birth) whose offspring remained islet autoantibody-negative during early childhood. CV-antibodies were detected in only 2/28 (7.1%) offspring who developed islet autoantibodies during follow up and in 7/51 (13.7%) offspring without islet autoantibodies (median follow up time 3.0 years, range 2.0-8.7). CV-IgG abs were detected in one mother (6.3%), whose offspring developed islet autoantibodies during early childhood, compared to 15 mothers (13.6%) with islet autoantibody-negative offspring (P=0.5). Also, partum levels of CV-IgG and CVB3-, -4-, and -5-IgM abs were similar in both groups (median 35 U, 0.08 index (I), 0.08, 0.05 vs. 35 U, 0.06 I, 0.11, and 0.06, resp., P> 0.35 in each case). These data make it unlikely that CV infections during pregnancy or in early childhood play a major role in the induction of islet autoimmunity in offspring of mothers or fathers with T1D or of mothers with gestational diabetes.


Subject(s)
Autoantibodies/immunology , Coxsackievirus Infections/immunology , Diabetes Mellitus, Type 1/immunology , Pregnancy Complications, Infectious/immunology , Pregnancy Complications, Infectious/virology , Pregnancy in Diabetics/immunology , Adult , Autoantibodies/genetics , Child , Child, Preschool , Coxsackievirus Infections/complications , Coxsackievirus Infections/genetics , Diabetes Mellitus, Type 1/etiology , Diabetes Mellitus, Type 1/genetics , Female , Humans , Immunoglobulin G/blood , Immunoglobulin M/blood , Infant , Male , Multicenter Studies as Topic , Pregnancy , Pregnancy in Diabetics/complications
17.
Exp Clin Endocrinol Diabetes ; 108(3): 151-63, 2000.
Article in English | MEDLINE | ID: mdl-10926309

ABSTRACT

A central finding of the UKPDS was that in type 2 diabetic patients, tight glycemic control with HbA1c targets as close to the normal range as possible must be achieved to further reduce diabetes related-complications, -mortality, and -cardiovascular disease, highlighting the need for new, optimized treatment strategies. With a focus on clinical efficacy, this paper discusses the results from the 20 major therapeutical trials published in the years 1997-1999, that evaluated the new insulinsensitizing thiazolidinediones Rosiglitazone and Pioglitazone and the new insulin-releasing potassium channel blockers Repaglinide and Nateglinide. While for Nateglinide, promising, but only preliminary data is available at current, Rosiglitazone, Pioglitazone, and Repaglinide have been shown appropriate for both mono- and combination therapy with current standard drug treatment of type 2 diabetes. Similar to the known, older antidiabetic drugs, the new agents discussed have comparable blood glucose lowering potentials with a dose-related capacity of 0.5 to 1.5% HbA1c reduction. These beneficial effects were both seen in drug-naive patients previously treated with diet only and in combination therapies where patients had previous antidiabetic standard drug treatment suggesting effectiveness of glitazones and glinides also in more advanced stages of the disease. Problems with adverse effects appeared minor although long-range implications of weight gain, edema, lowering of hemoglobin, increase of total cholesterol for the glitazones, and hypoglycemia for glinides warrant further consideration. What becomes clear from the variety of most recent mono- and combination treatment studies with as much as five different classes of antidiabetic drugs is that individually tailored therapies that recognize quality of life parameters and target the predominant features of metabolic pathology (such as early postprandial versus fasting hyperglycemia, degree of insulin resistance, progressive loss of 1-cell function) may become a feasible goal in the future.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Hypoglycemic Agents/therapeutic use , Phenylalanine/analogs & derivatives , Thiazolidinediones , Carbamates , Cyclohexanes/therapeutic use , Diabetes Mellitus, Type 2/blood , Drug Therapy, Combination , Glycated Hemoglobin/analysis , Humans , Hypoglycemic Agents/classification , Nateglinide , Phenylalanine/therapeutic use , Pioglitazone , Piperidines , Rosiglitazone , Thiazoles/therapeutic use
18.
Diabetes Care ; 23(7): 969-74, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10895848

ABSTRACT

OBJECTIVE: Environmental factors have been suggested to play an important role in the pathogenesis of type 1 diabetes. The aim of this study was to assess the influence of breast-feeding, vaccinations, and childhood viral diseases on the initiation of islet autoimmunity in early childhood. RESEARCH DESIGN AND METHODS: Data were prospectively collected from questionnaires obtained at birth, at 9 months of age, and at 2 years of age in 823 offspring from parents with type 1 diabetes. By 2 years of age, 31 offspring had islet antibodies, and 10 developed overt diabetes by the time of follow-up. RESULTS: In offspring from mothers with type 1 diabetes, duration of exclusive and total breast-feeding did not differ between islet antibody-positive and -negative children, regardless of HLA genotype, and breast-feeding of 3 months or longer was not associated with protection from antibody development or diabetes onset. In offspring from diabetic fathers, non-statistically significant reductions in exclusive and total breast-feeding times were observed in the antibody-positive cohort. Neither type nor quantity of vaccinations (including Bacille Calmette-Guerin vaccine; haemophilus influenzae vaccine; diphtheria, tetanus, and pertussis vaccine; tick-born encephalitis vaccine; or measles, mumps, and rubella vaccine) were associated with the development of islet antibodies and diabetes. Measles, mumps, and rubella were not reported in children with islet antibodies or diabetes. CONCLUSIONS: This study showed no evidence that proposed environmental factors affect islet antibody development in the first 2 years of life in offspring from parents with type 1 diabetes.


Subject(s)
Autoantibodies/blood , Breast Feeding , Diabetes Mellitus, Type 1/epidemiology , Diabetes Mellitus, Type 1/genetics , Milk, Human , Vaccination , Virus Diseases/immunology , Diabetes Mellitus, Type 1/immunology , Female , Germany , Humans , Immunization Schedule , Infant , Infant, Newborn , Islets of Langerhans/immunology , Male , Nuclear Family , Prospective Studies , Risk Factors , Surveys and Questionnaires
19.
Diabetes ; 49(6): 918-25, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10866043

ABSTRACT

Insulin immunization in animal models induces T-helper (Th) 2-like antibody subclass responses to insulin and other beta-cell antigens. The aim of this study was to determine whether exposure to insulin in humans resulted in a similar subclass bias of the humoral immune response. Levels of IgG subclass antibodies to insulin (IAs), GAD, and IA-2 were measured before and after treatment with insulin in the following groups of patients: 29 patients with newly diagnosed type 1 diabetes treated with intravenous and/or subcutaneous insulin; 10 newly diagnosed patients randomized to cyclosporin A (CsA) or placebo plus subcutaneous insulin for 12 months; and 14 islet cell antibody-positive relatives receiving either intravenous and subcutaneous insulin prophylaxis or no treatment. At the onset of diabetes, the major subclass distributions of insulin autoantibodies (IAAs) were IgG1 and, to a lesser extent, IgG4. After insulin treatment in the 29 new-onset patients, IAs were initially of the IgG1 subclass. IgG4-IAs appeared later, but at 12 months, they were at higher levels than IgG1-IAs in 11 patients. Responses were higher in children compared with adults and were higher in subjects with IAAs (P < 0.001). Insulin prophylaxis in relatives showed a similar profile, with a decline in levels of IgG1-IAs after cessation of daily subcutaneous insulin. Patients treated with CsA took longer to develop IAs and showed suppressed levels of IgG4-IAs; however, their levels of high-titer IgG1-IAs persistently rebounded after completion of CsA therapy. Despite the presence of IgG4-IAs in most insulin-treated patients and relatives, a shift to IgG4-anti-GAD or IgG4-IA-2 was not found for up to 3 years after the initiation of insulin therapy. While our findings need to be correlated with T-cell cytokine responses, we suggest that the strong IgG4-IA response in insulin-treated patients is consistent with an enhancement of Th2 immunity, but there is no evidence of subsequent spreading of potentially Th2-associated IgG4 responses to other autoantigens.


Subject(s)
Hypoglycemic Agents/therapeutic use , Immunoglobulin G/analysis , Insulin/immunology , Insulin/therapeutic use , Th2 Cells/immunology , Adolescent , Adult , Antibodies/analysis , Antibody Formation , Autoantibodies/analysis , Autoantigens/immunology , Child , Child, Preschool , Cyclosporine/therapeutic use , Diabetes Mellitus, Type 1/drug therapy , Diabetes Mellitus, Type 1/immunology , Diabetes Mellitus, Type 1/prevention & control , Glutamate Decarboxylase/immunology , Humans , Islets of Langerhans/immunology
20.
J Immunol ; 163(1): 525-32, 1999 Jul 01.
Article in English | MEDLINE | ID: mdl-10384157

ABSTRACT

The islet autoimmunity of preclinical type 1 diabetes remains poorly characterized in humans. In this paper, the IgG subclass response to the islet autoantigens insulin, glutamic acid decarboxylase, and IA-2 was studied sequentially from birth to diabetes onset or current follow-up in 26 autoantibody positive offspring of parents with diabetes. Islet autoantibody appearance was characterized by an early IgG1 peak response to one or more Ags, most commonly to insulin, at a median age of 2.2 yr (interquartile range, 2-2.9 yr). In five offspring, an acute fulminant beta-cell destruction and diabetes onset occurred during this initial Ab response. In the remainder, early Ab levels declined markedly, and Ab peaks against other beta cell Ags arose sequentially over several years suggesting regulation and spreading of autoimmunity. Second peak Ab responses to the same Ag were observed in only two offspring, both developing diabetes at this time. Two others developed diabetes with declining Ab levels. Abs of IgG1 subclass dominated against each Ag, and other subclasses, were usually only detected during peak IgG1 responses. The IgG4 response to insulin was exceptional, being dominant over IgG1 in four offspring and in five others appeared and/or persisted after IgG1 levels declined. These Th2-associated IgG4 responses were not correlated with protection from diabetes. The presence of IgG1-restricted responses to DA2 were associated with diabetes development. These findings suggest that type 1 diabetes has an early acute destructive phase of beta cell autoimmunity, which may be regulated and which spreads chronically until diabetes onset.


Subject(s)
Autoantibodies/biosynthesis , Diabetes Mellitus, Type 1/immunology , Immunodominant Epitopes/immunology , Immunoglobulin G/biosynthesis , Prediabetic State/immunology , Age Factors , Autoantibodies/blood , Child , Child, Preschool , Disease Progression , Follow-Up Studies , Humans , Immunoglobulin G/classification , Immunoglobulin Isotypes/biosynthesis , Immunoglobulin Isotypes/blood , Infant , Infant, Newborn , Islets of Langerhans/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...